Skip to main content (Press Enter).
Sign in
Skip auxiliary navigation (Press Enter).
Join/Renew
ASA Community
ASA Home
Code of Conduct
Volunteer
Skip main navigation (Press Enter).
Toggle navigation
Home
About Us
Join
Sub-Committees
-Mentoring Program Committee
-Funding Program Committee
-Next Generation Stewardship Committee
-Fellows Committee
-Membership Committee
-Scientific Working Group Proposal Committee
-Leadership-in-Practice Committee (LiPCom)
-Statisticians in Small Biotech
Overview
EC Meeting Minutes
History
BIOP Turns 40
Charter
Join
Related Links
Manual of Operations
Working Groups
Alzheimer's Disease
Bayesian Scientific Working Group
Cell & Gene Therapy
Centralized Statistical Monitoring and Quality Tolerance Limits
Covariate Adjustment Scientific Working Group
Efficiency+
Estimands in Oncology
Nonclinical Biostatistics
Pediatric Drug Development
Real World Evidence Scientific Working Group
Re-Randomization
Safety Scientific Working Group
Scientific Working Group for Neuroscience
Software Engineering Working Group
Statistical Methods in Oncology
Biopharmaceutical Software Working Group - Retired Group
Health Technology Assessment Scientific Working Group
Statistics and Pharmacometrics
Events
ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop
ASA Biopharmaceutical Section Nonclinical Biostatistics Conference
STATBOLIC 2025
Upcoming ASA Webinars
Biopharmaceutical Event Calendar
General Calendar
Media Contents
Webinar Archive
Podcasts
BIOP Youtube Channel
Biopharmaceutical Report
Directory
Awards
Best Nonclinical Paper
ASA Fellow Members in the Biopharmaceutical Section
Student Paper Competition
Scholarship Award
Past Award Winners
Women in Statistics in Data Science (WSDS) Conference Travel Award
Safety Scientific Working Group
Toggle navigation
Home
Who We Are
Who We Are
By-Laws
Past and Present Co-Chairs
History
Annual Reports
Workstreams
WS1 Interdisciplinary Safety Evalulation
WS2 Safety Monitoring Statistical Methodology
WS3 Integration of RWE and RCT for Safety Decision Making
Webinars
Publications
2025
Hendrickson, B.A., Drogaris, L., and Munsaka, M. Data Monitoring Committees. In Pharmacovigilance: A Practical Approach. Elsevier, St. Louis, MO, Second Edition, 2025.
Hendrickson, B.A., Rosenberg, T., and Setze, C. Product Aggregate Safety Assessment. In Pharmacovigilance: A Practical Approach. Elsevier, St. Louis, MO, Second Edition, 2025.
Munsaka, M.S., Introduction to Quantitative Methods and Visual Analytics in Drug Safety Data in Clinical Trials. In Pharmacovigilance: A Practical Approach. Elsevier, St. Louis, MO, Second Edition, 2025.
Verdugo, Maria., Wick-Urban, Bettina., Da Silva-Tillmann, Barbara. Benefit-Risk Management. In Pharmacovigilance: A Practical Approach. Chapter 15. Elsevier, St. Louis, MO, Second Edition, 2025.
2024
Hendrickson BA, McShea C, Ball G, Talbot S. How Aggregate Safety Assessment Planning Supports Investigational New Drug Safety Reporting Decisions. Ther Innov Regul Sci. 2024 Jul;58(4):579-590. doi: 10.1007/s43441-024-00634-5. Epub 2024 Mar 30. PMID: 38555342.
Gebel M, Renz C, Rodriguez L, Simonetti A, Yang H, Edwards B, Higginson JM, Charpentier N, Colopy M. A Survey to Assess the Current Status of Structured Benefit-Risk Assessment in the Global Drug and Medical Device Industry. Ther Innov Regul Sci. 2024 Jul;58(4):756-765.
Simonetti A, Colilla S, Edwards B, Kübler J, Lackey L, Rodriguez L, Talbot S, Yang H, Wang W, Williams D, Higginson JM. Key Opinion Leaders' Interviews to Inform the Future of Benefit-Risk Planning in the Medical Total Product Life Cycle of Global Pharmaceutical and Medical Device Organizations. Drug Saf. 2024 Sep;47(9):853-868.
2023
Hendrickson, B.A., Agarwal, A., Bennett, D., Kübler, K., McShea, C. and Tremmel, (2023). L. Value and Implementation of the Aggregate Safety Assessment Plan. Pharm Med 37(3):171-181
2022
Munsaka, M., Liu, M., Xing, y., Yang, H. (2022). Leveraging Machine Learning, Natural Language Processing, and Deep Learning in Drug Safety and Pharmacovigilance. In Data Science, AI, and Machine Learning in Drug Development. Yang, H. (Ed.). doi.org/10.1201/9781003150886
Hendrickson, Barbara A. The Aggregate Safety Assessment Plan – a valuable tool for clinical trial safety planning. Pharma Focus Asia. Issue 46: 24-27, 2022.
Waschbusch M, Rodriguez L, Brueckner A, Lee KJ, Li X, Mokliatchouk O, Tremmel L, Yuan SS. Global Landscape of Benefit-Risk Considerations for Medicinal Products: Current State and Future Directions. Pharmaceut Med. 2022 Aug;36(4):201-213. doi: 10.1007/s40290-022-00435-x. Epub 2022 Jul 3. PMID: 35780471.
2021
Buchanan J, Li M, Ni X, Wildfire J. A New Paradigm for Safety Data Signal Detection and Evaluation Using Open-Source Software Created by an Interdisciplinary Working Group. Ther Innov Drug Dev. (2021). doi.org/10.1007/s43441-021-00319-3
Hendrickson BA, Wang W, Ball G, Bennett D, Bhattacharyya A, Fries M, Kuebler J, Kurek R, McShea C, Tremmel L. Aggregate Safety Assessment Planning for the Drug Development Life-Cycle. Ther Innov Regul Sci. 2021 Jul;55(4):717-732. doi: 10.1007/s43441-021-00271-2. Epub 2021 Mar 23. PMID: 33755928.
Wang, W., Munsaka, M., Buchanan, J., & Li, J. (Eds.). (2021). Quantitative Drug Safety and Benefit Risk Evaluation: Practical and Cross-Disciplinary Approaches (1st ed.). Chapman and Hall/CRC. https://doi.org/10.1201/9780429488801
2020
Ball G, Kurek R, Hendrickson BA, Buchanan J, Wang WW, Duke SP, Bhattacharyya A, Li M, O'Brien D, Weigel J, Wang W, Jiang Q, Ahmad F, Seltzer JH, Herrero-Martinez E, Tremmel L. Global Regulatory Landscape for Aggregate Safety Assessments: Recent Developments and Future Directions. Ther Innov Regul Sci. 2020 Mar;54(2):447-461. doi: 10.1007/s43441-019-00076-4. Epub 2020 Jan 6. PMID: 32072595; PMCID: PMC7222952
Wang W, Nilsson M, Revis R, Crowe B. Interactive visualization for clinical safety data review. Biopharmaceutical Report 2020;27:2-8
2018
Zink RC. (2018).
Introduction to the Special Section for Sources of Safety Data and Statistical Strategies for Design and Analysis
.
Therapeutic Innovation & Regulatory Science
52: 140.
Zink RC, Marchenko O, Sanchez-Kam M, Ma H & Jiang Q. (2018).
Sources of safety data and statistical strategies for design and analysis: Clinical trials
.
Therapeutic Innovation & Regulatory Science
52: 141-158.
Izem R, Sanchez-Kam M, Ma H, Zink RC & Zhao Y. (2018).
Sources of safety data and statistical strategies for design and analysis: Post-market surveillance
.
Therapeutic Innovation & Regulatory Science
52: 159-169.
Marchenko O, Russek-Cohen E, Levenson M, Zink RC, Krukas-Hampel M & Jiang Q. (2018).
Sources of safety data and statistical strategies for design and analysis: Real world insights
.
Therapeutic Innovation & Regulatory Science
52: 170-186.
Ma H, Russek-Cohen E, Izem R, Marchenko O & Jiang Q. (2018).
Sources of safety data and statistical strategies for design and analysis: Transforming data into evidence
. Submitted to
Therapeutic Innovation & Regulatory Science
52: 187-198.
Wang, W., Whalen, E., Munsaka, M., Li, J., Fries, M., Kracht, K., Sanchez-Kam, M., Singh, K. Zhou, K. (2018). On Quantitative Methods for Clinical Safety Monitoring in Drug Development.
Statistics in Biopharmaceutical Research
,
10
(2), 85–97. https://doi.org/10.1080/19466315.2017.1409134
2017
Marchenko O, Jiang Q, Chuang-Stein C, Mehta C, Levenson M, Russek-Cohen E, Liu L, Sanchez-Kam M, Zink RC, Ke C, Ma H, Maca J & Park S. (2017).
Statistical considerations for cardiovascular outcome trials in patients with type 2 diabetes mellitus
.
Statistics in Biopharmaceutical Research
9: 347-360
.
.
Colopy M, Duke S, Ball G, Gordon R, Ahmad F, Jiang Q, Wang Wenquan & Wang William. (2016).
ASA Biopharm’s Safety Monitoring Working Group: Survey of statisticians, thought leaders and regulatory guidance
.
JSM Proceedings
3030-3042.
Fries M, Kracht K, Li J, Munsaka M, Sanchez-Kam M, Singh K, Wang W, Whalen E, Zhou K. (2016).
Safety monitoring methodology in the premarketing setting
.
JSM Proceedings
2247-2269.
.
Marchenko O, Jiang Q, Chakravarty A, Ke C, Ma H, Maca J, Russek-Cohen E, Sanchez-Kam M, Zink RC & Chuang-Stein C. (2015).
Evaluation and review of strategies to assess cardiovascular risk in clinical trials in patients with type 2 diabetes mellitus
.
Statistics in Biopharmaceutical Research
7: 253-266.
Skip Navigation Links
Privacy Policy
Report a Problem
Copyright © 2025 ASA. All rights reserved.
Powered by Higher Logic
×
Community Tags
Add a tag
x
User Tags may not contain the following characters: @ # $ & :